HCW Biologics Inc. (HCWB)
HCWB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/0001193125-26-134934-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | HCWB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001828673 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $54K |
| Net income | -$8.0M |
| Operating income | -$13.2M |
| Net margin | -14677.1% |
| Operating margin | -24270.7% |
| Revenue growth | -97.9% |
| Cash | $2.0M |
| Total assets | $24.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 33.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt regarding the Company's ability to continue as a going concern. 6 The accompanying condensed financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business." | 10-Q 2026-08-14 |
| Cash and burn | $741K cash; operating cash flow -$3.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,836,324 (2026-08-14); 2,151,607 a year earlier; 35,926,721 three years earlier. 1y figure adjusted for splits (1-for-6 overall); 3y figure adjusted for splits (1-for-240 overall). | Cover page 2026-08-14 |
| Reverse splits, 3 years | 2; latest 1-for-6 on 2026-06-30 | Source 2026-06-30 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-06-01 |
| Auditor | Crowe LLP, Indianapolis, Indiana, United States | PCAOB Form AP 2026-04-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $512K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $122K | -$5.2M | -$4.0M | $741K | $6.6M | $6.7M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $6.5M | $3.5M | -$1.6M | $1.2M | $6.6M | $6.5M | 10-Q/A 2026-08-14 |
| Q4 2025 2025-12-31 | $27K | $719K | -$3.4M | $2.0M | $6.8M | $54K | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | $16K | -$4.6M | -$3.2M | $1.1M | $6.8M | $422K | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $7K | -$1.9M | -$3.3M | $2.4M | $6.8M | $833K | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $5K | -$2.2M | -$3.5M | $1.1M | $13.9M | $1.4M | 10-Q/A 2026-08-14 |
| Q4 2024 2024-12-31 | $395K | -$3.4M | -$2.8M | $4.7M | $13.7M | $2.6M | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | $426K | -$3.9M | -$2.9M | $998K | $12.8M | $3.5M | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1 | 2026-10-02 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-10-01 |
Source: SEC EDGAR submissions feed, 342 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -24.2% |
| 1 month | -38.7% |
| 3 months | -73.6% |
| Year to date | -86.7% |
| 1 year | -94.8% |
| From 52-week high | -95.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SXTP | 60 Degrees Pharmaceuticals Inc. | $0.4938 | -4.65% | $1.7M |
| ENLV | Enlivex Ltd. | $1.12 | -5.88% | $1.7M |
| XRTX | XORTX Therapeutics Inc. Common Shares | $1.04 | -5.45% | $1.9M |
| ONCO | Onconetix Inc. | $2.91 | -9.35% | $1.9M |
| PPCB | Propanc Biopharma Inc. | $1.89 | -2.62% | $2.0M |
| ARTL | Artelo Biosciences Inc. | $1.70 | -17.87% | $1.6M |
| CMND | Clearmind Medicine Inc. Common Shares | $4.18 | -7.67% | $2.1M |
| SBFM | Sunshine Biopharma Inc. | $2.60 | -3.70% | $2.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier